Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12837 | 1.00 | KDM4E (0.55) | KDM4EALDH1A1LMNAHRH3KMT2A | |
| SCHEMBL12449658 | 1.00 | KDM4E (0.55) | KDM4EALDH1A1LMNAHRH3KMT2A | |
| SCHEMBL13102 | 0.90 | KDM4E (0.54) | KDM4ELMNAHRH3MAOBGAA | |
| SCHEMBL12449641 | 0.90 | KDM4E (0.54) | KDM4ELMNAHRH3MAOBGAA | |
| SCHEMBL13052 | 0.89 | HRH3 (0.56) | KDM4EALDH1A1HRH3MAOBHRH2 | |
| SCHEMBL12449644 | 0.89 | HRH3 (0.56) | KDM4EALDH1A1HRH3MAOBHRH2 | |
| SCHEMBL12449633 | 0.89 | HRH3 (0.56) | KDM4EALDH1A1HRH3MAOBHRH2 | |
| SCHEMBL13570088 | 0.88 | ALDH1A1 (0.43) | KDM4EALDH1A1LMNAHRH3 | |
| SCHEMBL12449700 | 0.88 | ALDH1A1 (0.46) | KDM4EALDH1A1LMNAHRH3 | |
| SCHEMBL12449698 | 0.88 | ALDH1A1 (0.46) | KDM4EALDH1A1LMNAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | KDM4E 1093/4885ALDH1A1 3185/4885LMNA 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.